Dynavax Announces $100 Million Accelerated Share Repurchase Program
11/11/24, 1:07 PM
Location
emeryvilleMoney
$100 million
Industry
biopharma
biotechnology
Type
agreement
Dynavax Technologies Corporation has entered into an Accelerated Share Repurchase transaction under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock. The ASR is part of the $200 million share repurchase program authorized by its Board of Directors in November 2024. Upon completion of this ASR, Dynavax will have $100 million remaining under the program
Company Info
Location
emeryville, california, united states
Additional Info
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap.